Bright Minds Biosciences
DRUG
11 hedge funds and large institutions have $628K invested in Bright Minds Biosciences in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
22% more funds holding
Funds holding: 9 → 11 (+2)
0.84% less ownership
Funds ownership: 1.54% → 0.7% (-0.84%)
79% less capital invested
Capital invested by funds: $2.93M → $628K (-$2.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$248K |
| 2 |
Jane Street
New York
|
+$55.4K |
| 3 |
VF
Virtu Financial
New York
|
+$32.7K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$13.4K |
| 5 |
BlackRock
New York
|
+$12.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.13M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
AdvisorShares Investments
Bethesda,
Maryland
| $314K | +$248K | +22,155 | +115% |
|
|
IC
2
Ikarian Capital
Dallas,
Texas
| $161K | +$13.4K | +1,192 | +6% |
|
|
3
Jane Street
New York
| $37K | +$55.4K | +4,940 | New |
|
|
QFA
4
Quattro Financial Advisors
The Woodlands,
Texas
| $32K | – | – | – |
|
|
VF
5
Virtu Financial
New York
| $22K | +$32.7K | +2,912 | New |
|
|
CCA
6
Checchi Capital Advisers
Beverly Hills,
California
| $21K | – | – | – |
|
|
7
BlackRock
New York
| $18K | +$12.6K | +1,126 | +91% |
|
|
BFM
8
Boothbay Fund Management
New York
| $17K | – | – | – |
|
9
UBS Group
Zurich,
Switzerland
| $5K | +$4.24K | +378 | +121% |
|
|
APC
10
Aspire Private Capital
Cornelius,
North Carolina
| $1K | – | – | – |
|
|
O
11
OrbiMed
New York
| – | -$2.13M | -132,120 | Closed |
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$538 | +48 | New |
|
DRUG Hedge Fund Activity: Q1 2022 in Review
11 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q1 2022, worth a combined $628K — down 79% from $2.93M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new DRUG positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $248K. The largest seller was OrbiMed, exiting entirely with an estimated $2.13M sold.
- 11 institutional investors held Bright Minds Biosciences (DRUG) as of Q1 2022, up from 9 in Q4 2021.
- Funds reported $628K of Bright Minds Biosciences stock for Q1 2022, down 79% quarter-over-quarter.
- 3 funds opened new Bright Minds Biosciences positions in Q1 2022 and 1 closed out, a net change of +2 holders.
- The largest Bright Minds Biosciences buyer in Q1 2022 was AdvisorShares Investments, an estimated $248K added.
- The largest Bright Minds Biosciences seller in Q1 2022 was OrbiMed, an estimated $2.13M sold.
Based on aggregated 13F filings for Q1 2022.